Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets ...

Stenoparib, a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, is currently being developed by Allarity for the treatment of advanced ovarian cancer. The drug has shown potential due to its ...

Stenoparib, a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, is currently being developed by Allarity for the treatment of advanced ovarian cancer. The drug has shown potential due to its ...

Lastly, we will discuss the relationship between PARylation and immune checkpoint inhibitors. Figure 1. Schematic model of PARylation-mediated protein degradation. Tankyrase promotes ...